Aucun résultat
Anne Gatignol’s research focuses on the control of the cellular responses to HIV infection, which enhance or inhibit viral replication. She characterized several cellular factors that contribute to the regulation of PKR during HIV replication in lymphocytes and astrocytes.
Prof. Gatignol’s lab also studies the interactions between viruses and the components of the RNA interference machinery. She characterized the relationship between TRBP and Dicer proteins in the RNA-induced silencing complex. She is analyzing the modifications of the RNAi pathway induced by HIV and their pathological consequences.
Prof. Gatignol’s lab also develops RNA-based technologies to target HIV, SARS-CoV-2 and their cellular cofactors to inhibit viral replication. The aim of this project is to use the active anti-HIV molecules expressed on a lentiviral vector for use in gene therapy and to develop RNA therapeutics against SARS-CoV-2 to be used intranasally as an antiviral treatment.
Alpuche-Lazcano SP, Scarborough RJ, Gatignol A. Retrovirology. 2024 Feb 29;21(1):5. doi: 10.1186/s12977-024-00637-y.
Chen MJ, Gatignol A, Scarborough RJ. Expert Opin Drug Discov. 2023 Feb;18(2):163-179. doi: 10.1080/17460441.2022.2117296.
Alpuche-Lazcano SP, Saliba J, Costa VV, Campolina-Silva GH, Marim FM, Ribeiro LS, Blank V, Mouland AJ, Teixeira MM, Gatignol A. PLoS Negl Trop Dis. 2021 May 28;15(5):e0009425. doi: 10.1371/journal.pntd.0009425.
Goguen RP, Del Corpo O, Malard CMG, Daher A, Alpuche-Lazcano SP, Chen MJ, Scarborough RJ, Gatignol A. Mol Ther Nucleic Acids. 2021 Jan 1;23:1020-1034. doi: 10.1016/j.omtn.2020.12.022.
Del Corpo O, Goguen RP, Malard CMG, Daher A, Colby-Germinario S, Scarborough RJ, Gatignol A. Mol Ther Nucleic Acids. 2019 Dec 6;18:815-830. doi: 10.1016/j.omtn.2019.10.011.
